Literature DB >> 23353709

Levetiracetam has opposite effects on alcohol- and cocaine-related behaviors in C57BL/6J mice.

J Elliott Robinson1, Meng Chen, Alice M Stamatakis, Michael C Krouse, Elaina C Howard, Sara Faccidomo, Clyde W Hodge, Eric W Fish, C J Malanga.   

Abstract

The antiepileptic drug levetiracetam (LEV) is a potential treatment for alcohol use disorders, yet few preclinical studies exist on its effects in animal models relevant to drug or alcohol abuse. We investigated the effects of LEV on locomotor stimulation following acute and repeated administration of alcohol or cocaine and on alcohol- and cocaine-mediated changes in responding for brain stimulation reward (BSR) in C57BL/6J mice. LEV alone (10.0-100.0 mg/kg intraperitoneally) had no significant effect on locomotor activity or intracranial self-stimulation. Pretreatment with LEV reduced acute locomotor stimulation by 2.0 g/kg alcohol, attenuated the development of locomotor sensitization to alcohol with repeated exposure, and produced a shift in the dose-response curve for alcohol on BSR threshold without affecting maximum operant response rate (MAX). Conversely, LEV pretreatment enhanced both acute locomotor stimulation by 15 mg/kg cocaine and development of locomotor sensitization following repeated exposure and produced a leftward shift in the dose-response curve for cocaine on BSR threshold without affecting MAX. Electrophysiological recordings in vitro showed that LEV reduced excitatory currents in both ventral tegmental area (VTA) dopamine neurons and nucleus accumbens (NAc) medium spiny neurons, consistent with a presynaptic effect. The opposite effects of LEV pretreatment on alcohol- and cocaine-related behaviors may predict its clinical utility in the treatment of patients with alcohol, but not psychostimulant abuse disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23353709      PMCID: PMC3656375          DOI: 10.1038/npp.2013.30

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  72 in total

1.  Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial.

Authors:  Christoph Richter; Susanne Effenberger; Tom Bschor; Udo Bonnet; Christian Haasen; Ulrich W Preuss; Andreas Heinz; Anna Förg; Katharina Volkmar; Till Glauner; Martin Schaefer
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

2.  MK-801 blocks the development of behavioral sensitization to the ethanol.

Authors:  R Camarini; R Frussa-Filho; M G Monteiro; H M Calil
Journal:  Alcohol Clin Exp Res       Date:  2000-03       Impact factor: 3.455

3.  A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam.

Authors:  Anna L Meehan; Xiaofeng Yang; Brian D McAdams; Lilian Yuan; Steven M Rothman
Journal:  J Neurophysiol       Date:  2011-06-08       Impact factor: 2.714

4.  Role of genotype in the development of locomotor sensitization to alcohol in adult and adolescent mice: comparison of the DBA/2J and C57BL/6J inbred mouse strains.

Authors:  Laverne C Melón; Stephen L Boehm
Journal:  Alcohol Clin Exp Res       Date:  2011-03-15       Impact factor: 3.455

5.  SV2 regulates neurotransmitter release via multiple mechanisms.

Authors:  Amy Nowack; Jia Yao; Kenneth L Custer; Sandra M Bajjalieh
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-11       Impact factor: 4.249

6.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

7.  Levetiracetam inhibits neurotransmitter release associated with CICR.

Authors:  Kouji Fukuyama; Shunsuke Tanahashi; Masanori Nakagawa; Satoshi Yamamura; Eishi Motomura; Takashi Shiroyama; Hisashi Tanii; Motohiro Okada
Journal:  Neurosci Lett       Date:  2012-03-28       Impact factor: 3.046

8.  Ethanol enhances glutamate transmission by retrograde dopamine signaling in a postsynaptic neuron/synaptic bouton preparation from the ventral tegmental area.

Authors:  Chunyu Deng; Ke-Yong Li; Chunyi Zhou; Jiang-Hong Ye
Journal:  Neuropsychopharmacology       Date:  2008-09-10       Impact factor: 7.853

9.  AMPA receptors and motivation for drug: effect of the selective antagonist NBQX on behavioural sensitization and on self-administration in mice.

Authors:  A Jackson; A N Mead; B A Rocha; D N Stephens
Journal:  Behav Pharmacol       Date:  1998-09       Impact factor: 2.293

Review 10.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

View more
  6 in total

Review 1.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

2.  Receptor Reserve Moderates Mesolimbic Responses to Opioids in a Humanized Mouse Model of the OPRM1 A118G Polymorphism.

Authors:  J Elliott Robinson; Eyal Vardy; Jeffrey F DiBerto; Vladimir I Chefer; Kate L White; Eric W Fish; Meng Chen; Eduardo Gigante; Michael C Krouse; Hui Sun; Annika Thorsell; Bryan L Roth; Markus Heilig; C J Malanga
Journal:  Neuropsychopharmacology       Date:  2015-04-16       Impact factor: 7.853

3.  Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice.

Authors:  Eric W Fish; Abigail E Agoglia; Michael C Krouse; R Grant Muller; J Elliott Robinson; C J Malanga
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

4.  Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL/6J mice.

Authors:  A Leslie Morrow; C J Malanga; Eric W Fish; Buddy J Whitman; Jeff F DiBerto; J Elliott Robinson
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

5.  Novel anticonvulsants for reducing alcohol consumption: A review of evidence from preclinical rodent drinking models.

Authors:  A E Padula; N S McGuier; W C Griffin; M F Lopez; H C Becker; P J Mulholland
Journal:  OA Alcohol       Date:  2013-02-01

6.  Chronic levetiracetam (Keppra®) treatment increases the reinforcing strength of cocaine in rhesus monkeys.

Authors:  Paul W Czoty; Robert W Gould; Cormac A O'Donovan; Michael A Nader
Journal:  Pharmacol Biochem Behav       Date:  2021-06-08       Impact factor: 3.697

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.